Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes
Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects. The aim of this study was to obtain a better understanding of the mechanism involved in the insulin sensitizing effect of pioglitazone. A total of 50 newly diagnosed patients with type 2 diabet...
Gespeichert in:
| Veröffentlicht in: | Endocrine Journal 2010, Vol.57(5), pp.423-430 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 430 |
|---|---|
| container_issue | 5 |
| container_start_page | 423 |
| container_title | Endocrine Journal |
| container_volume | 57 |
| creator | Nakano, Koji Hasegawa, Goji Fukui, Michiaki Yamasaki, Masahiro Ishihara, Kiyoshi Takashima, Tooru Kitagawa, Yoshihiro Fujinami, Aya Ohta, Mitsuhiro Hara, Hirokazu Adachi, Tetsuo Ogata, Masakazu Obayashi, Hiroshi Nakamura, Naoto |
| description | Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects. The aim of this study was to obtain a better understanding of the mechanism involved in the insulin sensitizing effect of pioglitazone. A total of 50 newly diagnosed patients with type 2 diabetes were enrolled in this study and divided into two groups, 25 of who were treated with 15 mg/day pioglitazone and 25 with 500 mg/day metformin for 12 weeks. Changes in various parameters of insulin resistance including lipoprotein subclass according to particle size determined by high performance liquid chromatography, as well as glucose metabolism, were monitored to determine the relationship between lipoprotein subclass and other insulin resistance parameters. Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels. Pioglitazone treatment, but not metformin treatment resulted in significant reductions in serum large very low-density lipoprotein (VLDL: 44.5-64.0 nm) and increases in serum adiponectin levels (both |
| doi_str_mv | 10.1507/endocrj.K10E-006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733118952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733118952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-e224a2f9ff3de1c1ef319977e3c108fe63033a0ddc13083213102bca7dd1c5903</originalsourceid><addsrcrecordid>eNo9kUFv3CAQhVHVqtmmvfdUcevJKRh7bR-raNNWjdRLe0YYBpsVBgdwI-cX92cUZzd7ATHzzRv0HkIfKbmhNWm-gFNehuPNT0oOBSH7V2hHWdUWVV2R12hHOtoWbVd3V-hdjEdCGKsr9hZdlYTuCeuaHfp30Bpkwl7j2fjBmiSevAPsHf4rgvFLxLMIYoIEIW6UcXGxxuEA0cQknIRcknZRxg3YmtnPwSfIQFx6aUWMWEjpw3M7-U0sGWkBR_MEuF-xwAPYYoYwgUgmrx3NMG5v7cP0LG_Nw2IUlmPwk0h-CGIe17wUO3i0K1ZGDM5HUFk7GXAp4keTRpzWGXC5tfv8-fgevdHCRvhwvq_Rn7vD79vvxf2vbz9uv94XMnuWCijLSpS605opoJKCZrTrmgaYpKTVsGfZREGUkpSRlpWUUVL2UjRKUVl3hF2jzyfd7MPDAjHxyUQJ1goH2U3eMEZpzqTMJDmRMvgYA2g-BzOJsHJK-BYvP8fLt3h5jjePfDqLL_0E6jLwkmcG7k7AMWczwAU4u35RrBteb8eL8gWQowiZYv8BXJ3ELQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733118952</pqid></control><display><type>article</type><title>Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes</title><source>J-STAGE Free</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nakano, Koji ; Hasegawa, Goji ; Fukui, Michiaki ; Yamasaki, Masahiro ; Ishihara, Kiyoshi ; Takashima, Tooru ; Kitagawa, Yoshihiro ; Fujinami, Aya ; Ohta, Mitsuhiro ; Hara, Hirokazu ; Adachi, Tetsuo ; Ogata, Masakazu ; Obayashi, Hiroshi ; Nakamura, Naoto</creator><creatorcontrib>Nakano, Koji ; Hasegawa, Goji ; Fukui, Michiaki ; Yamasaki, Masahiro ; Ishihara, Kiyoshi ; Takashima, Tooru ; Kitagawa, Yoshihiro ; Fujinami, Aya ; Ohta, Mitsuhiro ; Hara, Hirokazu ; Adachi, Tetsuo ; Ogata, Masakazu ; Obayashi, Hiroshi ; Nakamura, Naoto</creatorcontrib><description>Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects. The aim of this study was to obtain a better understanding of the mechanism involved in the insulin sensitizing effect of pioglitazone. A total of 50 newly diagnosed patients with type 2 diabetes were enrolled in this study and divided into two groups, 25 of who were treated with 15 mg/day pioglitazone and 25 with 500 mg/day metformin for 12 weeks. Changes in various parameters of insulin resistance including lipoprotein subclass according to particle size determined by high performance liquid chromatography, as well as glucose metabolism, were monitored to determine the relationship between lipoprotein subclass and other insulin resistance parameters. Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels. Pioglitazone treatment, but not metformin treatment resulted in significant reductions in serum large very low-density lipoprotein (VLDL: 44.5-64.0 nm) and increases in serum adiponectin levels (both <0.001). In the pioglitazone group, the change in large VLDL levels correlated positively with changes in HbA1c (r=0.468, P=0.0174), HOMA-IR (r=0.593, P=0.0014), very small LDL (r=0.714, P<0.0001) and net electronegative charged modified-LDL (r=0.412, P=0.0399), and inversely with changes in adiponectin level (r=-0.526, P=0.0061). The results in this study suggest that the hypoglycemic effect of pioglitazone is achieved mainly through improvement of hepatic insulin resistance, and that pioglitazone may have an antiatherosclerotic effect by decreasing serum atherogenic modified-LDL and by increasing adiponectin.</description><identifier>ISSN: 0918-8959</identifier><identifier>EISSN: 1348-4540</identifier><identifier>DOI: 10.1507/endocrj.K10E-006</identifier><identifier>PMID: 20160397</identifier><language>eng</language><publisher>Japan: The Japan Endocrine Society</publisher><subject>Adiponectin ; Age of Onset ; Body Fat Distribution ; Chromatography, Gel - methods ; Chromatography, High Pressure Liquid - methods ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Female ; Hepatic insulin resistance ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacology ; Hypolipidemic Agents - administration & dosage ; Hypolipidemic Agents - pharmacology ; Insulin Resistance ; Large VLDL ; Lipoprotein subclass particle size ; Lipoproteins - analysis ; Lipoproteins - blood ; Lipoproteins - classification ; Male ; Metformin - administration & dosage ; Metformin - pharmacology ; Middle Aged ; Particle Size ; Pioglitazone ; Thiazolidinediones - administration & dosage ; Thiazolidinediones - pharmacology ; Time Factors</subject><ispartof>Endocrine Journal, 2010, Vol.57(5), pp.423-430</ispartof><rights>The Japan Endocrine Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-e224a2f9ff3de1c1ef319977e3c108fe63033a0ddc13083213102bca7dd1c5903</citedby><cites>FETCH-LOGICAL-c540t-e224a2f9ff3de1c1ef319977e3c108fe63033a0ddc13083213102bca7dd1c5903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20160397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakano, Koji</creatorcontrib><creatorcontrib>Hasegawa, Goji</creatorcontrib><creatorcontrib>Fukui, Michiaki</creatorcontrib><creatorcontrib>Yamasaki, Masahiro</creatorcontrib><creatorcontrib>Ishihara, Kiyoshi</creatorcontrib><creatorcontrib>Takashima, Tooru</creatorcontrib><creatorcontrib>Kitagawa, Yoshihiro</creatorcontrib><creatorcontrib>Fujinami, Aya</creatorcontrib><creatorcontrib>Ohta, Mitsuhiro</creatorcontrib><creatorcontrib>Hara, Hirokazu</creatorcontrib><creatorcontrib>Adachi, Tetsuo</creatorcontrib><creatorcontrib>Ogata, Masakazu</creatorcontrib><creatorcontrib>Obayashi, Hiroshi</creatorcontrib><creatorcontrib>Nakamura, Naoto</creatorcontrib><title>Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes</title><title>Endocrine Journal</title><addtitle>Endocr J</addtitle><description>Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects. The aim of this study was to obtain a better understanding of the mechanism involved in the insulin sensitizing effect of pioglitazone. A total of 50 newly diagnosed patients with type 2 diabetes were enrolled in this study and divided into two groups, 25 of who were treated with 15 mg/day pioglitazone and 25 with 500 mg/day metformin for 12 weeks. Changes in various parameters of insulin resistance including lipoprotein subclass according to particle size determined by high performance liquid chromatography, as well as glucose metabolism, were monitored to determine the relationship between lipoprotein subclass and other insulin resistance parameters. Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels. Pioglitazone treatment, but not metformin treatment resulted in significant reductions in serum large very low-density lipoprotein (VLDL: 44.5-64.0 nm) and increases in serum adiponectin levels (both <0.001). In the pioglitazone group, the change in large VLDL levels correlated positively with changes in HbA1c (r=0.468, P=0.0174), HOMA-IR (r=0.593, P=0.0014), very small LDL (r=0.714, P<0.0001) and net electronegative charged modified-LDL (r=0.412, P=0.0399), and inversely with changes in adiponectin level (r=-0.526, P=0.0061). The results in this study suggest that the hypoglycemic effect of pioglitazone is achieved mainly through improvement of hepatic insulin resistance, and that pioglitazone may have an antiatherosclerotic effect by decreasing serum atherogenic modified-LDL and by increasing adiponectin.</description><subject>Adiponectin</subject><subject>Age of Onset</subject><subject>Body Fat Distribution</subject><subject>Chromatography, Gel - methods</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Female</subject><subject>Hepatic insulin resistance</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypolipidemic Agents - administration & dosage</subject><subject>Hypolipidemic Agents - pharmacology</subject><subject>Insulin Resistance</subject><subject>Large VLDL</subject><subject>Lipoprotein subclass particle size</subject><subject>Lipoproteins - analysis</subject><subject>Lipoproteins - blood</subject><subject>Lipoproteins - classification</subject><subject>Male</subject><subject>Metformin - administration & dosage</subject><subject>Metformin - pharmacology</subject><subject>Middle Aged</subject><subject>Particle Size</subject><subject>Pioglitazone</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Thiazolidinediones - pharmacology</subject><subject>Time Factors</subject><issn>0918-8959</issn><issn>1348-4540</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kUFv3CAQhVHVqtmmvfdUcevJKRh7bR-raNNWjdRLe0YYBpsVBgdwI-cX92cUZzd7ATHzzRv0HkIfKbmhNWm-gFNehuPNT0oOBSH7V2hHWdUWVV2R12hHOtoWbVd3V-hdjEdCGKsr9hZdlYTuCeuaHfp30Bpkwl7j2fjBmiSevAPsHf4rgvFLxLMIYoIEIW6UcXGxxuEA0cQknIRcknZRxg3YmtnPwSfIQFx6aUWMWEjpw3M7-U0sGWkBR_MEuF-xwAPYYoYwgUgmrx3NMG5v7cP0LG_Nw2IUlmPwk0h-CGIe17wUO3i0K1ZGDM5HUFk7GXAp4keTRpzWGXC5tfv8-fgevdHCRvhwvq_Rn7vD79vvxf2vbz9uv94XMnuWCijLSpS605opoJKCZrTrmgaYpKTVsGfZREGUkpSRlpWUUVL2UjRKUVl3hF2jzyfd7MPDAjHxyUQJ1goH2U3eMEZpzqTMJDmRMvgYA2g-BzOJsHJK-BYvP8fLt3h5jjePfDqLL_0E6jLwkmcG7k7AMWczwAU4u35RrBteb8eL8gWQowiZYv8BXJ3ELQ</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Nakano, Koji</creator><creator>Hasegawa, Goji</creator><creator>Fukui, Michiaki</creator><creator>Yamasaki, Masahiro</creator><creator>Ishihara, Kiyoshi</creator><creator>Takashima, Tooru</creator><creator>Kitagawa, Yoshihiro</creator><creator>Fujinami, Aya</creator><creator>Ohta, Mitsuhiro</creator><creator>Hara, Hirokazu</creator><creator>Adachi, Tetsuo</creator><creator>Ogata, Masakazu</creator><creator>Obayashi, Hiroshi</creator><creator>Nakamura, Naoto</creator><general>The Japan Endocrine Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2010</creationdate><title>Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes</title><author>Nakano, Koji ; Hasegawa, Goji ; Fukui, Michiaki ; Yamasaki, Masahiro ; Ishihara, Kiyoshi ; Takashima, Tooru ; Kitagawa, Yoshihiro ; Fujinami, Aya ; Ohta, Mitsuhiro ; Hara, Hirokazu ; Adachi, Tetsuo ; Ogata, Masakazu ; Obayashi, Hiroshi ; Nakamura, Naoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-e224a2f9ff3de1c1ef319977e3c108fe63033a0ddc13083213102bca7dd1c5903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adiponectin</topic><topic>Age of Onset</topic><topic>Body Fat Distribution</topic><topic>Chromatography, Gel - methods</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Female</topic><topic>Hepatic insulin resistance</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypolipidemic Agents - administration & dosage</topic><topic>Hypolipidemic Agents - pharmacology</topic><topic>Insulin Resistance</topic><topic>Large VLDL</topic><topic>Lipoprotein subclass particle size</topic><topic>Lipoproteins - analysis</topic><topic>Lipoproteins - blood</topic><topic>Lipoproteins - classification</topic><topic>Male</topic><topic>Metformin - administration & dosage</topic><topic>Metformin - pharmacology</topic><topic>Middle Aged</topic><topic>Particle Size</topic><topic>Pioglitazone</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Thiazolidinediones - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakano, Koji</creatorcontrib><creatorcontrib>Hasegawa, Goji</creatorcontrib><creatorcontrib>Fukui, Michiaki</creatorcontrib><creatorcontrib>Yamasaki, Masahiro</creatorcontrib><creatorcontrib>Ishihara, Kiyoshi</creatorcontrib><creatorcontrib>Takashima, Tooru</creatorcontrib><creatorcontrib>Kitagawa, Yoshihiro</creatorcontrib><creatorcontrib>Fujinami, Aya</creatorcontrib><creatorcontrib>Ohta, Mitsuhiro</creatorcontrib><creatorcontrib>Hara, Hirokazu</creatorcontrib><creatorcontrib>Adachi, Tetsuo</creatorcontrib><creatorcontrib>Ogata, Masakazu</creatorcontrib><creatorcontrib>Obayashi, Hiroshi</creatorcontrib><creatorcontrib>Nakamura, Naoto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakano, Koji</au><au>Hasegawa, Goji</au><au>Fukui, Michiaki</au><au>Yamasaki, Masahiro</au><au>Ishihara, Kiyoshi</au><au>Takashima, Tooru</au><au>Kitagawa, Yoshihiro</au><au>Fujinami, Aya</au><au>Ohta, Mitsuhiro</au><au>Hara, Hirokazu</au><au>Adachi, Tetsuo</au><au>Ogata, Masakazu</au><au>Obayashi, Hiroshi</au><au>Nakamura, Naoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes</atitle><jtitle>Endocrine Journal</jtitle><addtitle>Endocr J</addtitle><date>2010</date><risdate>2010</risdate><volume>57</volume><issue>5</issue><spage>423</spage><epage>430</epage><pages>423-430</pages><issn>0918-8959</issn><eissn>1348-4540</eissn><abstract>Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects. The aim of this study was to obtain a better understanding of the mechanism involved in the insulin sensitizing effect of pioglitazone. A total of 50 newly diagnosed patients with type 2 diabetes were enrolled in this study and divided into two groups, 25 of who were treated with 15 mg/day pioglitazone and 25 with 500 mg/day metformin for 12 weeks. Changes in various parameters of insulin resistance including lipoprotein subclass according to particle size determined by high performance liquid chromatography, as well as glucose metabolism, were monitored to determine the relationship between lipoprotein subclass and other insulin resistance parameters. Both pioglitazone and metformin treatment were associated with significant reductions in hyperglycemia, HOMA-IR and HbA1c levels. Pioglitazone treatment, but not metformin treatment resulted in significant reductions in serum large very low-density lipoprotein (VLDL: 44.5-64.0 nm) and increases in serum adiponectin levels (both <0.001). In the pioglitazone group, the change in large VLDL levels correlated positively with changes in HbA1c (r=0.468, P=0.0174), HOMA-IR (r=0.593, P=0.0014), very small LDL (r=0.714, P<0.0001) and net electronegative charged modified-LDL (r=0.412, P=0.0399), and inversely with changes in adiponectin level (r=-0.526, P=0.0061). The results in this study suggest that the hypoglycemic effect of pioglitazone is achieved mainly through improvement of hepatic insulin resistance, and that pioglitazone may have an antiatherosclerotic effect by decreasing serum atherogenic modified-LDL and by increasing adiponectin.</abstract><cop>Japan</cop><pub>The Japan Endocrine Society</pub><pmid>20160397</pmid><doi>10.1507/endocrj.K10E-006</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-8959 |
| ispartof | Endocrine Journal, 2010, Vol.57(5), pp.423-430 |
| issn | 0918-8959 1348-4540 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733118952 |
| source | J-STAGE Free; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adiponectin Age of Onset Body Fat Distribution Chromatography, Gel - methods Chromatography, High Pressure Liquid - methods Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Female Hepatic insulin resistance Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacology Hypolipidemic Agents - administration & dosage Hypolipidemic Agents - pharmacology Insulin Resistance Large VLDL Lipoprotein subclass particle size Lipoproteins - analysis Lipoproteins - blood Lipoproteins - classification Male Metformin - administration & dosage Metformin - pharmacology Middle Aged Particle Size Pioglitazone Thiazolidinediones - administration & dosage Thiazolidinediones - pharmacology Time Factors |
| title | Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A27%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20pioglitazone%20on%20various%20parameters%20of%20insulin%20resistance%20including%20lipoprotein%20subclass%20according%20to%20particle%20size%20by%20a%20gel-permeation%20high-performance%20liquid%20chromatography%20in%20newly%20diagnosed%20patients%20with%20type%202%20diabetes&rft.jtitle=Endocrine%20Journal&rft.au=Nakano,%20Koji&rft.date=2010&rft.volume=57&rft.issue=5&rft.spage=423&rft.epage=430&rft.pages=423-430&rft.issn=0918-8959&rft.eissn=1348-4540&rft_id=info:doi/10.1507/endocrj.K10E-006&rft_dat=%3Cproquest_cross%3E733118952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733118952&rft_id=info:pmid/20160397&rfr_iscdi=true |